March 2, 2020 / 1:56 PM / in a month

BRIEF-EyePoint Pharma Announces Positive Topline 36-Month Follow-Up Data For Second Phase 3 Study Of YUTIQ

March 2 (Reuters) - EyePoint Pharmaceuticals Inc:

* EYEPOINT PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE 36-MONTH FOLLOW-UP DATA FOR SECOND PHASE 3 STUDY OF YUTIQ®

* EYEPOINT PHARMACEUTICALS INC - SAFETY DATA SHOWED NO UNANTICIPATED SIDE EFFECTS AT EACH FOLLOW-UP TIMEPOINT IN YUTIQ STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below